Financial Performance - The company's operating revenue for 2023 was CNY 191,727,433.84, an increase of 2.74% compared to the previous year[4]. - The net profit attributable to shareholders decreased by 7.77% to CNY 33,147,743.71, while the net profit after deducting non-recurring gains and losses fell by 15.19% to CNY 23,705,314.63[4][6]. - Basic earnings per share decreased by 16.28% to CNY 0.36, reflecting the decline in net profit[4][7]. Assets and Equity - Total assets at the end of the reporting period increased by 10.80% to CNY 422,029,659.53, driven by investments in laboratory expansion and equipment[5][7]. - Shareholders' equity attributable to the company rose by 4.54% to CNY 342,653,461.26, with net assets per share increasing by 4.71% to CNY 3.71[5][6]. Operational Changes - The company expanded its laboratory space and purchased new equipment, which increased costs and expenses during the reporting period[6][7]. - The company is currently in the process of expanding its testing capabilities, which is expected to enhance future performance[6][7]. Government Support - Government subsidies recognized in the current period increased by 17.95%, contributing to non-recurring gains and losses growth of 18.21%[6]. Reporting and Caution - The financial data presented is preliminary and unaudited, and investors are advised to exercise caution[2][8]. - The annual report will provide finalized figures and further insights into the company's performance[2][8].
中纺标(873122) - 2023 Q4 - 年度业绩